Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | CFO, Secretary, Treasurer | May 17, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date May 17, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2031-05-17 | Direct | 300,000 |
Reported balance
After 2021-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-17 · Grant · Acquired 300,000 · Balance 300,000 F1: Options were awarded by the Board of Directors as part of Mr. Bregman's employment agreement. F2: The options will vest over a three-year period, commencing one year from the date of issuance. The first third will vest on May 17, 2022 |
Filing footnotes · ownership attribution and instrument terms
F1: Options were awarded by the Board of Directors as part of Mr. Bregman's employment agreement.
F2: The options will vest over a three-year period, commencing one year from the date of issuance. The first third will vest on May 17, 2022
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed Jul 7, 2021 21:00 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantOptions · Derivative | 300,000 | $0.06 Strike: $0.06 | $16,860.00 |
DisclosureSEC source: 0001863113-21-000002 · primary_doc.xml · derivative · entry 1 Bregman Marc · CIK 0001863113 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-05-17 F1 · shares: Options were awarded by the Board of Directors as part of Mr. Bregman's employment agreement. F2 · derivative.exercise_date: The options will vest over a three-year period, commencing one year from the date of issuance. The first third will vest on May 17, 2022 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.